The safety and efficacy of EV were validated in the phase III open-label, randomized, multicenter EV-301 study, which included patients with advanced bladder cancer who had previously been treated with platinum-based chemotherapy and PD(L)-1 inhibitors. Here, CD274 is linked to urinary bladder cancer.